Referee report. For: Recent advances in treatment for Benign Prostatic Hyperplasia [version 1; referees: 2 approved]

In 2015, the treatment of benign prostatic hyperplasia (BPH) saw significant advancements driven by personalized medicine and medical technology. While traditional treatments like alpha-blockers and 5-alpha reductase inhibitors remained prevalent, new approaches such as phosphodiesterase type 5 inhibitors like tadalafil showed promise in improving symptoms without adverse sexual side effects. Surgical innovations included less invasive techniques like the prostatic urethral lift and prostatic artery embolization, though the latter required more rigorous data. Laser techniques, particularly holmium laser enucleation of the prostate (HOLEP), became standard due to their efficacy and reduced morbidity. The future of BPH management was expected to focus on understanding complex interactions beyond prostate obstruction and developing novel surgical techniques like aquablation. Overall, the emphasis was on individualized treatment plans tailored to patient needs, leveraging new technologies to minimize side effects.